MANKIND — Mankind Pharma Balance Sheet
0.000.00%
- IN₹1.06tn
- IN₹1.02tn
- IN₹103.35bn
Annual balance sheet for Mankind Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 10,897 | 20,172 | 12,943 | 15,216 | 33,865 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 7,398 | 5,669 | 11,106 | 12,184 | 9,374 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 28,222 | 39,066 | 44,068 | 43,279 | 65,682 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 18,646 | 19,917 | 23,896 | 30,170 | 31,387 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 50,733 | 63,726 | 91,477 | 97,154 | 119,633 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12,586 | 13,534 | 26,235 | 18,631 | 21,197 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 15,880 | 16,506 | 29,925 | 22,802 | 26,002 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 34,853 | 47,220 | 61,552 | 74,352 | 93,631 |
Total Liabilities & Shareholders' Equity | 50,733 | 63,726 | 91,477 | 97,154 | 119,633 |
Total Common Shares Outstanding |